Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands		Total	Common Stock		Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance, (in shares) at Dec. 31, 2022	[1]		12,479,000
Beginning balance at Dec. 31, 2022	[1]	$ 833,252	$ 1		$ 1,608,330	$ (7,599)	$ (767,480)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		47,084			47,084
Issuance of common stock upon exercise of stock options (in shares)			150,000
Issuance of common stock upon exercise of stock options		306			306
Issuance of common stock under employee stock purchase plan (in shares)			49,000
Issuance of common stock under employee stock purchase plan		1,894			1,894
Issuance of common stock in connection with restricted stock units, net of tax (in shares)			20,000
Issuance of common stock in connection with restricted stock units, net of tax		(457)			(457)
Other comprehensive (loss) income		7,505				7,505
Net loss		(234,632)					(234,632)
Ending balance, (in shares) at Dec. 31, 2023	[1]		12,698,000
Ending balance at Dec. 31, 2023	[1]	654,952	$ 1		1,657,157	(94)	(1,002,112)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		33,144			33,144
Issuance of common stock upon exercise of stock options (in shares)			62,000
Issuance of common stock upon exercise of stock options		154			154
Issuance of common stock under employee stock purchase plan (in shares)			48,000
Issuance of common stock under employee stock purchase plan		1,248			1,248
Issuance of common stock in connection with restricted stock units, net of tax (in shares)			61,000
Issuance of common stock in connection with restricted stock units, net of tax		(76)			(76)
Issuance of common stock as payment for acquisition of IPR&D asset (in shares)			1,875,000
Issuance of common stock for acquisition of IPR&D		36,011			36,011
Other comprehensive (loss) income		385				385
Net loss		$ (342,994)					(342,994)
Ending balance, (in shares) at Dec. 31, 2024		14,743,777	14,744,000	[1]
Ending balance at Dec. 31, 2024	[1]	$ 382,824	$ 1		1,727,638	291	(1,345,106)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		$ 41,829			41,829
Issuance of common stock upon exercise of stock options (in shares)		3,750	3,000
Issuance of common stock upon exercise of stock options		$ 42			42
Issuance of common stock under employee stock purchase plan (in shares)			52,000
Issuance of common stock under employee stock purchase plan		365			365
Issuance of common stock in connection with restricted stock units, net of tax (in shares)			173,000
Issuance of common stock in connection with restricted stock units, net of tax		(1)			(1)
Issuance of common stock in connect with contingent consideration milestone (in shares)			625,000
Issuance of common stock in connect with contingent consideration milestone		5,894			5,894
Issuance of common stock in connection with PIPE financing (in shares)			3,754,000
Issuance of common stock in connection with PIPE financing		57,774	$ 1		57,773
Issuance of common stock as payment for acquisition of IPR&D asset (in shares)			1,900,000
Issuance of common stock for acquisition of IPR&D		33,972			33,972
Other comprehensive (loss) income		(49)				(49)
Net loss		$ (274,448)					(274,448)
Ending balance, (in shares) at Dec. 31, 2025		21,251,353	21,251,000
Ending balance at Dec. 31, 2025		$ 248,202	$ 2		$ 1,867,512	$ 242	$ (1,619,554)

[1] 1. Amounts previously reported have been retroactively adjusted to reflect the 1-for-20 reverse stock split effected on May 30, 2025. See Note 2